Clinical Trials Browser

Phase 1/2 × Solid Tumors × E-3810 × Clear all

NCT01283945 2024-07-25

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Solid Tumors